{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:15:15Z","timestamp":1780323315706,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.seminoncol.2026.152486","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:22:24Z","timestamp":1773825744000},"page":"152486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pregnancy during pembrolizumab therapy for triple-negative breast cancer with onset of congenital hypothyroidism: Case report, literature review, and caution for clinical practice"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9779-9331","authenticated-orcid":false,"given":"Antonin","family":"Vagnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Ferraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-5733","authenticated-orcid":false,"given":"Marie-Blanche","family":"Valnet Rabier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2026.152486_bib0001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14740\/wjon1177","article-title":"Cancer during pregnancy: the oncologist overview","volume":"10","author":"Hepner","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0002","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0003","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0004","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. KEYTRUDA (pembrolizumab) - Cancer du sein. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/p_3420797\/fr\/keytruda-pembrolizumab-cancer-du-sein accessed October 16, 2024."},{"key":"10.1016\/j.seminoncol.2026.152486_bib0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0007","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.24.00372","article-title":"Academic uphill battle to personalize treatment for patients with stage II\/III triple-negative breast cancer","volume":"42","author":"Kok","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0008","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1600-0897.2009.00737.x","article-title":"ORIGINAL ARTICLE: PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T Cells in a pregnancy murine model","volume":"62","author":"Wafula","year":"2009","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2021.2404","article-title":"Malignant melanoma treated with pembrolizumab during pregnancy: A case report and review of the literature","volume":"15","author":"Anami","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/AOG.0000000000004434","article-title":"Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy","volume":"138","author":"Polnaszek","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0014","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2308135","article-title":"Severe immune-related enteritis after in utero exposure to pembrolizumab","volume":"389","author":"Baarslag","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1159\/000540000","article-title":"A case report of metastatic gastric cancer treated with pembrolizumab during pregnancy","volume":"51","author":"Piemonti","year":"2024","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/biomedicines13010140","article-title":"Successful pregnancy outcome in a patient treated with pembrolizumab and exposed to fluoro-deoxyglucose (18F-FDG) PET\/CT: case report and review of literature","volume":"13","author":"Mastricci","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0017","first-page":"239","article-title":"Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy","volume":"104","author":"Menzer","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0018","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0019","first-page":"762","article-title":"Pregnancy in a patient with metastatic uveal melanoma treated with nivolumab","volume":"19","author":"Haiduk","year":"2021","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000657","article-title":"Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition","volume":"30","author":"Bucheit","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/cancers15010173","article-title":"Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase\u00ae spontaneous reporting system","volume":"15","author":"Noseda","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5625","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0023","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/aogs.14729","article-title":"Breast cancer during pregnancy\u2014The oncologist\u2019s point of view","volume":"103","author":"Matikas","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1084\/jem.20050019","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0025","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.1002031","article-title":"The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance","volume":"187","author":"D\u2019Addio","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0026","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0027","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0028","doi-asserted-by":"crossref","first-page":"e550","DOI":"10.1016\/S1470-2045(21)00525-8","article-title":"Immunotherapy for cancer treatment during pregnancy","volume":"22","author":"Borgers","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0029","doi-asserted-by":"crossref","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO Endocrine side effects of cancer immunotherapy 2017. https:\/\/doi.org\/10.1530\/ERC-17-0358.","DOI":"10.1530\/ERC-17-0358"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111961","article-title":"Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: a systematic review and meta-analysis","volume":"133","author":"Yang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0031","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0033","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0001-4079(19)30188-8","article-title":"Effets endocriniens et m\u00e9taboliques des immunoth\u00e9rapies anticanc\u00e9reuses (d\u2019apr\u00e8s les recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019endocrinologie)","volume":"202","author":"W\u00e9meau","year":"2018","journal-title":"Bull Acad\u00e9mie Natl M\u00e9decine"},{"key":"10.1016\/j.seminoncol.2026.152486_bib0034","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:12:28Z","timestamp":1780319548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0093775426000333"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152486","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy during pembrolizumab therapy for triple-negative breast cancer with onset of congenital hypothyroidism: Case report, literature review, and caution for clinical practice","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152486"}}